Cost-effectiveness of statins for primary prevention of coronary heart disease in Japan

被引：0
|
作者：
Ikeda, Shunya
Kobayashi, Makoto
机构：
[1] Int Univ Hlth & Welfare, Dept Pharmaceut Sci, Ohtawara, Japan
[2] Crecon R&C Tokyo, Tokyo, Japan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2007年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：S225 / S226
页数：2
相关论文
共 50 条
  • [41] Cost-effectiveness of statins
    Huse, DM
    Russell, MW
    Miller, JD
    Kraemer, DF
    D'Agostino, RB
    Ellison, RC
    Hartz, SC
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (11): : 1357 - 1363
  • [42] Primary Prevention of Coronary Heart Disease With Statins It's Not About the Money
    Schwartz, J. Sanford
    [J]. CIRCULATION, 2011, 124 (02) : 130 - 132
  • [43] Comparing Two Cost-Effectiveness Studies of Statins for the Primary Prevention of Cardiovascular Disease: Are Statins Cost-Effective From a Korean Health System Perspective?
    Park, Haesuk
    Rascati, Karen L.
    [J]. CLINICAL THERAPEUTICS, 2009, 31 (12) : 2916 - 2918
  • [44] Cost-effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States
    Boettiger, David C.
    Newall, Anthony T.
    Phillips, Andrew
    Bendavid, Eran
    Law, Matthew G.
    Ryom, Lene
    Reiss, Peter
    Mocroft, Amanda
    Bonnet, Fabrice
    Weber, Rainer
    El-Sadr, Wafaa
    Monforte, Antonella D'Arminio
    Wit, Stephane
    Pradier, Christian
    Hatleberg, Camilla, I
    Lundgren, Jens
    Sabin, Caroline
    Kahn, James G.
    Kazi, Dhruv S.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 (03)
  • [45] ECONOMICS OF INTERVENTION ON BLOOD CHOLESTEROL FOR CORONARY HEART-DISEASE PREVENTION - EVIDENCE FOR COST-EFFECTIVENESS
    RECKLESS, JPD
    [J]. ATHEROSCLEROSIS, 1989, 79 (01) : 94 - 94
  • [46] Establishing the cost-effectiveness of statins in the primary prevention of CHD using a quasi Markov model
    Dewilde, S
    Davies, A
    Hutton, J
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 664 - 665
  • [47] Cost-effectiveness analysis of rheumatic heart disease prevention strategies
    Manji, Rizwan A.
    Witt, Julia
    Tappia, Paramjit S.
    Jung, Young
    Menkis, Alan H.
    Ramjiawan, Bram
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2013, 13 (06) : 715 - 724
  • [48] Commentary: Beyond 10-year risk: A cost-effectiveness analysis of statins for the primary prevention of cardiovascular disease
    Shah, Aditya
    Sharma, Kamal
    Rawal, Shalin
    Sisodia, Rhea
    Bhatt, Parjanya
    Christian, Cleris
    Konat, Ashwati
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [49] Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal
    Pinto, Carlos Gouveia
    Carrageta, Manuel Oliveira
    Miguel, Luis Silva
    [J]. VALUE IN HEALTH, 2008, 11 (02) : 154 - 159
  • [50] Cost-effectiveness of Rosuvastatin in the prevention of ischemic heart disease in Portugal
    Gouveia-Pinto, C
    Carrageta, M
    Silva-Miguel, L
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A102 - A102
12345